1. Raffaella Ravinetto, Chair
A REVIEW OF THE MARKETS FOR QUALITY-ASSURED PRODUCTS Markets for quality-assured products
Raffaella Ravinetto, Chair
Copenhagen, Denmark September 2017

2. Markets for quality-assured products
Lack of quality  morbidity, mortality, resistances (often undetected, mostly in vulnerable populations)
Quality must be built into a product  quality assurance systems 
Many interacting factors: QA, availability, affordability, innovation, regulation, pharmacovigilance, supply …
Many stakeholders/roles, e.g. manufactures and procurers
WHO medicines PQ: “a quiet revolution in public health” (t’Hoen)
Sixteen years after its launch: where do we stand?
Copenhagen, Denmark September 2017

3. Markets for quality-assured products
: which is the way forward?
HIV, malaria, TB: healthy competition among quality-assured manufacturers/products
New medicines (hepatitis C, SRH, NTDs…..): can we achieve the same? How?
Diagnostics: can we achieve the same? How?
Expanding PQ across the Essential Medicines List , e.g. antibiotics, NCDs: can we achieve the same? How?
What challenges for manufacturers (and procurers)?
Copenhagen, Denmark September 2017

4. Raffaella Ravinetto, Chair
A REVIEW OF THE MARKETS FOR QUALITY-ASSURED PRODUCTS Managing vaccines supplies and eliminating shortages
Raffaella Ravinetto, Chair
Copenhagen, Denmark September 2017

5. Managing vaccines supplies and eliminating shortages
No single preventive health intervention is more cost-effective than immunization
It averts an estimated 2 to 3 million deaths/year
If global vaccination coverage improved:
Additional 1.5 million deaths could be avoided
Some19.5 million infants would get basic vaccines
Global coverage has stalled at 86% during past year
Expanding global immunization coverage is crucial to achieving the Sustainable Development Goals
Copenhagen, Denmark September 2017

6. Managing vaccines supplies and eliminating shortages
Vaccine coverage depends on a variety of factors, including QA, price, availability, affordability, regulation, innovation, supply …. “closely inter-linked in the vaccine ecosystem”
Vaccine coverage depends on a variety of roles and stakeholders, including manufactures and procurers
A careful balance is required between both demand and supply, and cost and value
Which factors and needs to be taken into account when seeking that balance?
Copenhagen, Denmark September 2017